Secondary Acute Leukemia in Sarcoma Patients: A Population-Based Study.

Area of Science:

• Oncology
• Hematology
• Cancer Epidemiology

Background:

• Secondary acute leukemia is a rare but serious complication following cancer treatment.
• Understanding the incidence and risk factors for secondary leukemia in sarcoma patients is crucial for risk stratification and management.

Purpose of the Study:

• To compare the incidence of secondary acute leukemia in sarcoma patients versus the general population.
• To identify patient, tumor, and treatment-related factors associated with the development of secondary acute leukemia in sarcoma survivors.

Main Methods:

• Utilized data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry (1973-2008).
• Included 72,945 sarcoma patients; employed multivariable competing risk analysis and observed-to-expected ratios.
• Assessed risk factors including radiation therapy, disease stage, gender, diagnosis year, and histology.

Main Results:

• Sarcoma patients showed a higher incidence of secondary acute leukemia (observed-to-expected ratios: 3.67 for ALL, 3.41 for AML, 1.6 for AML).
• Increased risk was associated with radiation therapy (HR 1.67), distant disease (HR 2.67), male gender (HR 1.53), and specific histologies (Ewing sarcoma HR 9.95, osteosarcoma HR 5.06).
• 10-year cumulative incidence of secondary acute leukemia was 0.3% with radiation therapy vs. 0.1% without (P=.02).

Conclusions:

• Sarcoma patients, particularly those with Ewing sarcoma and osteosarcoma, exhibit an elevated risk of secondary acute leukemia.
• Radiation therapy and chemotherapy appear to contribute to this increased risk, although the absolute risk remains low.
• Further research may refine risk assessment and inform survivorship care for sarcoma patients.